CMC Blog

The Process of Decarboxylation
October 20th, 2017

Decarboxylation is the process of removing a carboxyl group (a carbon atom double-bonded to an oxygen atom) from a molecule. In the cannabis world, this process occurs when a carbon atom is removed from a carboxylic acid (namely THCa, and CBDa).

There is little to no naturally occurring THC/CBD in the plant prior to decarboxylation. It is an essential process whether performed by the LP or the patient. Heating your cannabis (via vaporizing, smoking, or by cooking) will cause a chemical bond to break off of the THCa molecule and convert it to THC. The same thing occurs when CBD is formed from CBDa.

Once your cannabis has been decarboxylated it can be consumed in its present state. Any capsule or oil based products from your licensed producer have already been decarboxylated. Your non-decarboxylated herbal cannabis however must still be heated to receive the full medicinal effect. This is usually achieved by vaporization.  

Part of the reason vaporizing is recommended over smoking is due to the decarboxylation process. Vaporization allows for even heating at a specific temperature. This can be important because the temperature settings on your vaporizer can allow for more efficient decarboxylation than smoking, which ultimately means you will likely use less product.

Decarboxylation of cannabis for the purpose of making edible products can be a tricky process and is not typically recommended. Instead we suggest asking your educator to help you find a product that has already been decarboxylated that you can simply add to your food.

If you have any other questions about the decarboxylation process please call our patient care centre at 888-282-7763 for further information.

CANABO MEDICAL ANNOUNCES NEW & INNOVATIVE SELF-REFERRAL SLEEP AID PROGRAM
October 19th, 2017

October 19th, 2017 – Vancouver, BC – Canabo Medical Inc. (TSXV: CMM) (OTCQB: CAMDF) (“Canabo” or the “Company”) is pleased to announce that it has launched its Self-Referral Sleep Aid program, a first of its kind in Canada. Patients with sleep issues are now welcome to book a medical clinic appointment directly with no prior requirement for a physician’s referral.

Dr. Michael Verbora, Medical Director of Canabo, commented: “Insomnia is a condition that affects millions of Canadians. We know that poor sleep habits and non-restorative sleep contributes to worsening physical and mental health. Many Canadians struggle to find options that can provide relief with tolerable side effects, which are drawbacks of many pharmaceutical sleep options. Canabo has identified specific cannabis strains that are very effective in treating insomnia with minimal side effects. We have developed a sleep protocol to identify patients whom are best suited for our self-referral program. Patients with sleep issues can now complete this process using an on-line self-referral form (CMClinic.ca).”

The Canadian Sleep Society (CSS) and the Canadian Sleep and Circadian Network (CSCN) reported; “over 25% of Canadians suffer from sleep disorders, a percentage that increases with aging.”[1]

John Philpott, CEO of Canabo, commented: “We are delighted to expand this much needed service to millions of Canadians. As Canabo now operates 19 clinics across the country we feel that this self referral initiative will provide much needed assistance to many Canadians that suffer from sleep disorders. We have protocols and methodologies in place to ensure smooth processing for Sleep Aid patients, who can now quickly book an appointment by calling 1-888-282-7763 or by completing our user-friendly on-line self-referral system.”

 

About the Company

Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis. Established in 2014, Canabo now has 19 clinics across Canada, with additional locations planned to open in 2017. Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

Forward Looking Statements

Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions, which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

 

For further information, please contact:

Ms. Bianca Müller

Telephone: +1-902-334-1700
Email: media@cmclinic.ca

www.canabocorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

[1] https://css-scs.ca/files/resources/publications/2015_CSS_CSCN_Report_PE_workshop.pdf

Cannabis Oil Titration
October 16th, 2017

Once you’ve been prescribed a cannabis oil, your next step will be finding your optimal dose. Ultimately, your optimal dose will depend on several factors including how well your body metabolizes the product, but also the cannabinoid (THC, CBD) concentrations of the oil you are taking. Whether it is a CBD oil, a THC oil or a mixed oil, we always recommend starting low and going slow until symptom alleviation is achieved. 

The body metabolizes ingested cannabis differently than inhaled cannabis and therefore patients should not guess how much cannabis oil should be consumed based on the amount of dried cannabis they have used previously.  Furthermore, those who have recently switched to a new type of oil or to a new licensed producer, should adjust their dosing accordingly to avoid any adverse side effects that may be caused by an unwanted increase in THC.  Patients may sometimes find that their dose in millilitres (mL) is higher than their prescribed amount in grams (g). If you feel this may be you, please review our post on cannabis oil equivalency factors

Due to the complexity of the cannabis plant and variability between products we recommend the following when titrating your cannabis oil.  

  • Always start low and go slow! 
  • Titrate slower for products containing more THC.
  • Track and monitor your dosage (mgTHC/mgCBD), onset, duration and effects. 
  • Search for symptom relief with no adverse side effects. 

If you’ve been prescribed a cannabis oil you should have additionally received a titration schedule from your patient educator. If you did not receive a schedule, or have further questions about dosing and/or titration of your cannabis oil, please call our patient care centre at 888-282

 

Splitting your Medical Document
October 12th, 2017

When a physician writes a medical document that document must be sent to one single licensed producer and thus you will only be able to buy your product from that producer. Sometimes, however, it may be practical to have your monthly quantity split between multiple producers.

Typically, we only recommend this for patients prescribed more than one gram per day.

Splitting your prescription between producers means you will be able to order part of your monthly quantity from one producer and part of that quantity from another. Below are numerous reasons why splitting a prescription may or may not be for you.

  • Pros
    • If the product you seek is often unavailable splitting between producers can open up more availability.  
    • This can also lead to a greater number of products available (IE: more CBD strains)
    • Some patients prefer to order different products from different producers (IE: Cannabis oil from one, herbal cannabis from another).
  • Cons

    • The patient will have multiple producers they will need to keep track of. This includes possession limits, ordering etc.
    • Patients may have to pay more shipping fees than they would if registered with a single producer due to smaller order quantities and multiple deliveries.
    • If the split is not done properly patients may experience issues based on the quantities prescribed and the quantities the licensed producers provide. 

 

Remember that splitting your prescription may only be done at your doctors discretion. If you think that splitting your prescription may be beneficial to you then we recommend speaking to your physician and patient educator during your next visit! If you have any further questions about your prescription or licensed producer please call our patient care centre at 888-282-7763.

 

CANABO MEDICAL RECEIVES $310,000 GRANT FOR LARGE OPIOID REDUCTION STUDY
October 5th, 2017

October 5th, 2017 – Vancouver, BC – Canabo Medical Inc. (TSXV: CMM) (OTCQB: CAMDF) (“Canabo” or the “Company”) is pleased to report that it will receive a $310,000.00 Research Grant to conduct a study on the reduction of opioids for patients prescribed medical cannabis.

The study, perhaps the largest of its kind, will involve 1,000 patients currently using opioids to manage chronic pain. It will examine whether the use of opioids among patients experiencing chronic pain increase or decrease following the prescription of medical cannabis. Opioid deaths are one of the most serious concerns facing physicians in Canada and around the world.

John Philpott, Canabo’s CEO commented: “We are delighted to play a leading role in this type of research in Canada.  The study’s methodology has already been approved by the Ethics Review Board at Acadia University which will greatly assist in having the study’s results published in Medical Journals across Canada and around the world. We believe this is just the beginning for other such research contracts”.

In addition, The Company wishes to announce that, subject to TSX Venture Exchange approval, it has granted incentive stock options to certain directors, officers, and consultants to purchase up to an aggregate of 1,000,000 common shares exercisable on or before October 4, 2022 at a price of 0.45c per share.

 

About the Company
Canabo wholly owns and operates Cannabinoid Medical Clinics, or CMClinics, Canada’s largest physician led referral-only clinics for medical cannabis.  Established in 2014, Canabo now has 19 clinics across Canada, with additional locations planned to open in 2017.  Canabo operates referral-only medical clinics dedicated to evaluating the suitability of prescribing, and monitoring cannabinoid treatments for patients suffering from chronic pain and disabling illnesses. Clinics operated by Canabo are staffed by physicians and qualified health care practitioners specifically trained to assess patient suitability for cannabinoid treatment, recommend treatment regimes, and monitor treatment progress.

 

Forward Looking Statements
Except for historical information, this press release contains forward-looking statements, which reflect Canabo Medical Inc.’s current expectations regarding future events. These forward-looking statements involve known and unknown risks and uncertainties that could cause Canabo’s actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, the Company’s ability to access capital, the successful and timely completion of opening clinics, regulatory changes, competition, approvals and other business and industry risks.

The forward-looking statements in this press release are also based on a number of assumptions which may prove to be incorrect. Forward-looking statements contained in this press release represent views only as of the date of this release and are presented for the purpose of assisting potential investors in understanding Canabo’s business and may not be appropriate for other purposes. Canabo does not undertake to update forward-looking statements, whether written or oral, that may be made from time to time by or on its behalf, except as required under applicable securities legislation. Investors are cautioned not to rely on these forward-looking statements and are encouraged to consult with a professional investment advisor.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information, please contact:

Ms. Bianca Müller
Telephone: +1-902-334-1700
Email: media@cmclinic.ca
www.canabocorp.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Contact Us

Phone: 1-888-282-7763
Fax: 1-844-320-9652

Our Patient Care Centre is open Monday through Friday from 7:30am to 7:00pm (EST) 

 

Ontario: 

Barrie, ON 
11 Lakeside Terrace, 2nd Floor

Bracebridge, ON
345 Ecclestone Drive

Burlington, ON
2951 Walkers Line, 3rd Floor, Suite 305  

Hamilton, ON
414 Victoria Ave., Suite M8  

Kingston, ON 
725 Arlington Park Place  

London, ON
130 Thompson Road 

Ottawa, ON  
1385 Bank St., Suite 305

St Catharines, ON 
Niagara Health Center, 180 Vine Street South, Suite 104

Stoney Creek, ON
35 Upper Centennial Pkwy., 2nd Floor  

Toronto, ON 
1 Eglinton Ave. E., Suite 407

Atlantic: 

Sackville, NB
112 Main Street, Unit D

St. John’s, NL
8-10 Rowan St., Suite 206

Halifax, NS 
5991 Spring Garden Rd., Suite 440

Wolfville, NS
2 – 4 Little Road


Western: 

Edmonton, AB
11010-101 St. NW, Suite 608

Calgary, AB
70 Country Hills Landing NW, Suite 103   

Chilliwack, BC
9181 Main Street, Suite 214  

Kelowna, BC
3975 Lakeshore Road, Suite 302